Cowen and Company’s Milestone Pharmaceuticals MIST Stock Holding History

Cowen and Company’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,000	Closed	-$20K	–	710
2022 Q3	$20K	Buy	+14,000	New	+$106K	﹤0.01%	345
2021 Q2	–	Sell	-5,166	Closed	-$30K	–	650
2021 Q1	$30K	Buy	+5,166	New	+$37.8K	﹤0.01%	427
2020 Q4	–	Sell	-11,990	Closed	-$88K	–	483
2020 Q3	$88K	Buy	+11,990	New	+$85.9K	0.01%	266

Other funds holding MIST

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cowen and Company's MIST Position: Q4 2022 in Review

Cowen and Company sold out of Milestone Pharmaceuticals (MIST) in Q4 2022, closing a stake of 14,000 shares — an estimated $20K sold.

Cowen and Company first reported a position in MIST in Q3 2020 and held it in 3 quarters. The position peaked at $88K in Q3 2020. 56 funds tracked by Wall St. Rank hold MIST as of Q4 2022.

Cowen and Company reported no remaining Milestone Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Cowen and Company sold 14,000 Milestone Pharmaceuticals shares in Q4 2022, an estimated $20K.
Cowen and Company first reported a position in Milestone Pharmaceuticals in Q3 2020 and held it in 3 quarters.
Cowen and Company's Milestone Pharmaceuticals position peaked at $88K in Q3 2020.
56 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2022.

Based on Cowen and Company's 13F filing for Q4 2022, filed 9 Feb 2023.